Table 1 Demographics and baseline characteristics of patients.
Variable | ET | CY + ET | ||
|---|---|---|---|---|
Total | Percentage (%) | Total | Percentage (%) | |
Case, n | 50 | 100.00 | 85 | 100.00 |
Sex | ||||
Female | 50 | 100.00 | 85 | 100.00 |
Age (mean) | 61 | 63 | ||
≥ 65 | 32 | 64 | 55 | 65.00 |
< 65 | 18 | 36 | 30 | 35.00 |
Receptor expression | ||||
ER+ | 50 | 100.00 | 85 | 100.00 |
PR+ | 17 | 34 | 29 | 35.00 |
HER2− | 50 | 100.00 | 85 | 100.00 |
Numbers of metastasis organ | ||||
1 | 5 | 10.00 | 10 | 12.00 |
2 | 26 | 52.00 | 45 | 53.00 |
> 2 | 19 | 38.00 | 30 | 35.00 |
Previous adjuvant chemotherapy | ||||
Yes | 24 | 48.00 | 38 | 45.00 |
No | 26 | 52.00 | 47 | 55.00 |
Previous adjuvant endocrinotherapy | ||||
Yes | 22 | 44.00 | 35 | 41.00 |
No | 28 | 56.00 | 50 | 59.00 |
ECOG-PS | ||||
0 | 27 | 54.00 | 45 | 53.00 |
1 | 23 | 46.00 | 40 | 47.00 |
Therapy | ||||
CY + Letrozole | – | – | 50 | 59.00 |
CY + Fulvestrant | – | – | 35 | 41.00 |
Letrozole | 21 | 42.00 | – | – |
Fulvestrant | 29 | 58.00 | – | – |
Disease control | ||||
CR + PR + SD | 35 | 70.00 | 62 | 73.00 |
PD | 15 | 30.00 | 23 | 27.06 |
